Cadila Healthcare Falls 9% After U.S. FDA Issues Warnings Letter
The Company has taken multiple steps after the inspection to address the observations received from US FDA during the inspection. The Company will continue to take all necessary steps to ensure that the US FDA is fully satisﬁed with our remediation of the above facility.
Management notes: We are confident of responding to US FDA to address the observations within the statutory time permitted in the letter. This warning letter does not affect the existing business of the Company in the US and the existing product supplies from the Moraiya facility with continue.
View: Hold company has strong compliance mechanism earlier Zydus Cadila has successfully completed USFDA audits of formulations manufacturing facility at Baddi, and AP! manufacturing facilities at Ankleshwar and Dabhasa during the year.